[Stenting in superficial femoral artery and usCRP: Multicentric study SAFE in 255 patients].
OBJECTIVE
To evaluate mid-term primary patency of the femoral artery stenting in correlation with usCRP level and characteristics of the population, morphological aspect of the lesions and interventional techniques.


METHODS
Patients were prospectively included in a multicenter study (18 centers in France) after stenting (SMART, Cordis Johnson & Johnson, Issy-les-Moulineaux, France) of the superficial femoral artery (SFA). Inclusion and exclusion criteria were based on recommendations and every day practice of the centers.


RESULTS
Thus 255 patients (183 men; mean age: 69 years; range 44-92) were included. Technical success of the SFA stenting was 100% without any complications and primary angiographic success 97%. usCRP level increased significantly (p < 0.05) between before and 24h after SFA stenting. In the subgroup of patients without initial inflammation (n = 157), usCRP increased significantly (p < 0.05) in the group of patient with initial thrombosis and additional intervention (graft, amputation, angioplasty on other arterial bed) in the same procedure compared to the remaining patients. Restenosis rate was 12.4% (26/209 patients) at 7 ± 2 months. Before stenting, usCRP level was not predictive of a restenosis, whereas after stenting, an increase of the 24h usCRP level was significantly higher in the subgroup of patient with an occlusion at mid-term (8 patients; p < 0.05).


CONCLUSIONS
This study demonstrated good patency at 7 months of SFA stenting with nitinol SMART with an increase of the usCRP level 24h after stenting in favour of the presence of an occlusion at mid-term follow-up.
Beregi
Jean-Paul
JP
CHRU de Lille, hôpital cardiologique, service de radiologie, 59037 Lille cedex, France. jpberegi@gmail.com
Lehalle
Bertrand
B
Cardon
Jean-Marie
JM
Pillet
Jean-Christophe
JC
Chabanier
Alain
A
Sibé
Maxime
M
Aubry
Pascal
P
de Cassin
Patrice
P
Raffin
Jean-Bernard
JB
Lecointre
Bruno
B
Vernhet
Hélène
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000497:Alloys; D000792:Angiography; D017130:Angioplasty / Q000379:methods*; D001157:Arterial Occlusive Diseases / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D002097:C-Reactive Protein / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007383:Intermittent Claudication / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D007511:Ischemia / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D007866:Leg / Q000098:blood supply*; D018810:Magnetic Resonance Angiography; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011475:Prosthesis Failure; D012008:Recurrence; D012307:Risk Factors; D015607:Stents; D013927:Thrombosis / Q000097:blood; D014057:Tomography, X-Ray Computed; D014654:Vascular Patency / Q000502:physiology
D000497:Alloys; C013616:nitinol; D002097:C-Reactive Protein